Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study
Abstract Purpose This study aimed to evaluate the efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma (DLBCL). Methods A retrospective analysis of 16 elderly patients with DLBCL who received selinexor-based regimens as firs...
Saved in:
| Main Authors: | Jing Li, Jingjing Ge, Tingting Chen, Jianghua Cao, Xiaohua He, Shulan Wang, Hang Yang, Yu Wang, Peng Sun, Jiajia Huang, Shan Liu, Zhiming Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14295-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01) -
Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma
by: Seiichi Okabe, et al.
Published: (2025-06-01) -
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma
by: Omar Alhalabi, et al.
Published: (2025-02-01) -
Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
by: Andrew Whiteley, et al.
Published: (2025-05-01) -
Selinexor’s Immunomodulatory Impact in Advancing Multiple Myeloma Treatment
by: Kereshmeh Tasbihi, et al.
Published: (2025-03-01)